Urartu Özgür Şafak Şeker

This paper develops a bispecific anti-EGFR/HER2 antibody to enhance antitumor effects by targeting both receptors and improving immune responses.

The paper introduces RNAGEN, a GAN-based model to generate synthetic RNA sequences that bind to target proteins, validated with in vitro experiments for SOX2.

UTRGAN generates 5' UTR sequences optimized for higher translation efficiency and gene expression, outperforming existing UTRs in multiple metrics.

This study engineers E. coli to secrete a toxin targeting HER2+ breast cancer cells, demonstrating efficient binding and cell killing in vitro.

This study identifies three peptides that inhibit mHtt fibril formation in vitro, offering potential therapeutic leads for Huntington's disease.

The paper presents an engineered living material using E. coli biofilm proteins and laccase enzymes to degrade fluoroquinolone antibiotics in water.

The paper develops a platform combining yeast and phage display to screen peptide therapeutics for neurodegenerative diseases, identifying candidates that inhibit amyloid fibril formation.

This paper introduces a protein secretion system for gram-negative bacteria to enable targeted protein delivery for therapeutic applications.

This study glycosylates alkaline phosphatase in E. coli using N-linked glycosylation to improve enzyme stability and performance under various conditions.

This study develops two biosensors for detecting urea and uric acid, key renal biomarkers, using genetic circuits and tests their performance in human blood serum.

This paper improves whole cell biosensors by integrating neural networks, achieving faster response times and higher accuracy in detecting analyte concentrations.

The paper develops a genetic circuit biosensor to rapidly detect nanoparticle toxicity using an engineered heat shock response mechanism, achieving high precision in one hour.